Home » Stocks » CRDF

Cardiff Oncology, Inc. (CRDF)

Stock Price: $19.57 USD 0.42 (2.19%)
Updated November 24, 4:00 PM EST - Market closed
After-hours: $20.20 +0.63 (3.22%) Nov 24, 7:48 PM

Stock Price Chart

Key Info

Market Cap 691.30M
Revenue (ttm) 339,315
Net Income (ttm) -20.24M
Shares Out 35.32M
EPS (ttm) -1.45
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day November 24
Last Price $19.57
Previous Close $19.15
Change ($) 0.42
Change (%) 2.19%
Day's Open 19.60
Day's Range 18.24 - 20.63
Day's Volume 956,112
52-Week Range 0.70 - 20.63

More Stats

Market Cap 691.30M
Enterprise Value 656.29M
Earnings Date (est) Mar 18, 2021
Ex-Dividend Date n/a
Shares Outstanding 35.32M
Float 31.78M
EPS (basic) -1.45
EPS (diluted) -1.45
FCF / Share -0.63
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 2.32M
Short Ratio 1.74
Short % of Float 7.29%
Beta 1.55
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 2,037.35
PB Ratio 19.20
Revenue 339,315
Operating Income -16.88M
Net Income -20.24M
Free Cash Flow -14.62M
Net Cash 35.01M
Net Cash / Share 0.99
Gross Margin -3,217.54%
Operating Margin -4,973.63%
Profit Margin -5,965.80%
FCF Margin -4,309.17%
ROA -41.07%
ROE -84.38%
ROIC 2,288.00%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (3)

Buy 3
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(39.65% upside)
Current: $19.57
Target: 27.33
*Average 12-month price target from 3 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth-35.34%-25.14%32.63%21.82%11.65%8.07%-42.44%74.78%-3%-
Gross Profit0.24-0.22-1.31-1.35-0.320.260.260.450.260.27
Operating Income-16.68-17.29-25.60-40.15-25.27-14.95-10.69-4.85-2.98-5.38
Net Income-16.41-16.46-24.91-39.20-27.47-14.33-11.81-11.57-2.24-5.45
Shares Outstanding5.972.330.480.420.360.
Earnings Per Share-2.80-8.26-51.76-93.30-87.12-63.36-50.40-64.08-16.56-56.16
Operating Cash Flow-13.27-13.20-23.28-31.04-22.12-12.73-7.32-4.93-1.93-2.09
Capital Expenditures-0.070.02-0.10-0.82-2.23-0.30-0.65-0.27--0.03
Free Cash Flow-13.34-13.18-23.38-31.86-24.35-13.03-7.97-5.20-1.93-2.12
Cash & Equivalents10.2011.458.2337.8967.4927.2925.8410.820.700.06
Total Debt1.73-1.3316.5416.4714.950.52--2.34
Net Cash / Debt8.4711.456.8921.3651.0212.3425.3210.820.70-2.28
Book Value7.3110.086.5119.7748.708.3520.392.17-4.23-5.00
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Cardiff Oncology, Inc.
Country United States
Employees 12
CEO Mark Erlander

Stock Information

Ticker Symbol CRDF
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: CRDF


Cardiff Oncology, a clinical-stage biotechnology company, develops drugs for the treatment of cancer. Its lead drug candidate is onvansertib, a Polo-like Kinase 1 selective adenosine triphosphate competitive inhibitor that is in Phase Ib/II clinical trial in acute myeloid leukemia (AML); has completed a Phase I clinical trial in advanced solid tumors; and Phase Ib/II clinical trial for metastatic colorectal cancer in combination with FOLFIRI and Avastin. The company's onvansertib is also in Phase II clinical trial in combination with Zytiga for metastatic castration-resistant prostate cancer. In addition, it develops therapeutics, such as belinostat (Beleodaq); quizartinib (AC220), a development stage FLT3 inhibitor; and bortezomib (Velcade) for the treatment of leukemias, lymphomas, and solid tumor cancers. The company primarily serves pharmaceutical companies. Cardiff Oncology, Inc. has a research collaboration with Nektar Therapeutics for the treatment of colorectal cancer. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2020. Cardiff Oncology, Inc. was founded in 1999 and is headquartered in San Diego, California.